BioOrbit's zero-gravity platform adopted by top 5 pharma by 2027
Resolves: At least one of the top 5 global pharmaceutical companies (by revenue) signs a binding agreement with BioOrbit to use its zero-gravity platform for drug development by June 30, 2027.
user-generated· adoption
BioOrbit's zero-gravity platform adopted by top 5 pharma by 2027
Market overview
BioOrbit's proprietary zero-gravity biomanufacturing platform has demonstrated 30% higher drug efficacy in preclinical models. Major pharmaceutical companies are likely to license or partner with BioOrbit to integrate this technology into their pipelines.
adoption prediction market
- Implied probability (Yes)
- 75%
- Closes
- 2027-06-30
About this prediction
Resolution criteria
At least one of the top 5 global pharmaceutical companies (by revenue) signs a binding agreement with BioOrbit to use its zero-gravity platform for drug development by June 30, 2027.
Source: user-generated
More adoption markets
- Daily active crypto users surpass 100 million by mid-2026 — 60% Yes
- Kalshi’s market share in crypto derivatives surpasses 5% by Q4 2027 — 55% Yes
- Kalshi's crypto perpetual futures launch by 2026-Q4 — 75% Yes
- Family offices double down on crypto-adjacent mining firms within 6 months — 72% Yes
- Nigeria's crypto transaction volume exceeds $5B in 2026 — 80% Yes
- AI and crypto groups increase political ad spending in 2026 midterms — 80% Yes
- Crypto and AI groups double political ad spending by 2027 — 75% Yes
- Crypto billionaire Harborne will increase donations to Farage by 20% by Mar 2027 — 60% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…